- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Events & Workshops
NICE recommends Bayer’s prostate cancer drug for routine NHS use
2 September 2016 • Author: Niamh Louise Marriott, Digital Content Producer
When radium-223 was previously appraised by NICE, it was only recommended for people who had already received docetaxel treatment. It was not recommended for people for whom docetaxel was not suitable.
This meant people who had not received docetaxel or for whom docetaxel was not suitable had to access radium-223 through the cancer drugs fund (CDF).
Following the decision to reform the CDF, NICE has been assessing the clinical and cost effectiveness of drugs currently in the old CDF.
The company submitted updated cost-effectiveness analyses comparing radium-223 with the current care available for people who have not received docetaxel, and for whom docetaxel is unsuitable. This new information meant the committee could agree that radium-223 was a cost-effective use of NHS resources.
The previously agreed confidential patient access scheme for radium-223 remains unchanged.
Professor Carole Longson, NICE, said, “I am pleased we have been able to broaden our recommendations for radium-223. Patients with prostate cancer will surely benefit from this drug being available for routine NHS use. I hope we’ll see more drugs like this move into routine NHS use after companies have been able to better demonstrate cost-effectiveness.”
The NHS now has a legal obligation to make radium-223 available to all eligible people, if they and their doctor agree it is the right treatment.
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) EUROGENTEC F.P.S. Food and Pharma Systems Srl IDBS JEOL Europe L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Panasonic Biomedical Sales Europe B.V. PerkinElmer Inc ReAgent Russell Finex Limited Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Watson-Marlow Fluid Technology Group Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Yusen Logistics